Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Pindolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Pindolol undergoes extensive metabolism in animals and man. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. About 6% to 9% of an administered intravenous dose is excreted by the bile into the feces. (en)
|
http://linked.open.../drugbank/synonym
| - Pindolol (en)
- Blockin L (en)
- Blocklin L (en)
- Calvisken (en)
- Cardilate (en)
- Decreten (en)
- Durapindol (en)
- Pectobloc (en)
- Pinbetol (en)
- Pynastin (en)
- Visken (en)
- Betapindol (en)
- Prinodolol (en)
- 1-(1H-indol-4-Yloxy)-3-(propan-2-ylamino)-propan-2-ol (en)
- 1-(1H-indol-4-Yloxy)-3-(isopropylamino)propan-2-ol (en)
- 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole (en)
- Blocklin-L (en)
- Carvisken (en)
- Glauco-visken (en)
- Pindololum (en)
- 1-(1H-indol-4-Yloxy)-3-[(1-methylethyl)amino]propan-2-ol (en)
|
http://linked.open...drugbank/toxicity
| - LD<sub>50</sub>=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm. (en)
|
http://linked.open...umeOfDistribution
| |
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Magnesium, potassium and zinc needs increased. (en)
- Take without regard to meals. Avoid alcohol. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - "DrugSyn.org":http://www.drugsyn.org/Pindolol.htm (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...logy/drugbank/pKa
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Rapidly and reproducibly absorbed (bioavailability greater than 95%). (en)
|